References
- P. C. Appelbaum and P. A. Hunter, The fluoroquinolone antibacterials: past, present and future perspectives, Int. J. Antimicrob. Agents 16 (2000) 5-15; DOI: 10.1016/S0924-8579(00)00192-8.
- D. C. Hooper, Quinolone Antimicrobial Agents (Eds. D. C. Hooper and E. Rubinstein), AMS Press, Washington 2003, pp. 3-40.
- S. Emami, A. Shafiee and A. Foroumadi, Structural features of new quinolones and relationship to antibacterial activity against Gram-positive bacteria, Mini Rev. Med. Chem. 6 (2006) 375-386; DOI: 10.2174/138955706776361493.
- K. E. Brighty and T. D. Gootz, The chemistry and biological profile of trovafloxacin, J. Antimicrob. Chemother. 39 (1997) 1-14; DOI: 10.1093/jac/39.suppl_2.1.
- M. P. Montanari, M. Prenna, M. Mingoia, S. Ripa and P. E. Varaldo, In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones, Chemotherapy 44 (1998) 85-93; DOI: 10.1159/000007097.
- J. Vincent, R. Teng, D. K. Dalvie and H. L. Friedman, Pharmacokinetics and metabolism of single oral doses of trovafloxacin, Am. J. Surg. 176 (1998) 8S-13S; DOI: 10.1016/S0002-9610(98)00213-X.
- D. Scuster, C. Laggner and T. Lagner, Why drugs fail - A Study on Side Effects in New Chemical Entities, in Antitargets. Prediction and Prevention of Drug Side Effects (Ed. R. Vaz and T. Klabunde), Wiley WCH Verlag GmbH & Co. KGaA, Weinheim 2008, pp. 3-22.
- M. J. Liguori, M. G. Anderson, S. Bukofzer, J. McKim, J. F. Pregenzer, J. Retief, B. B. Spear and J. F. Waring, Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin, Hepatology 41 (2005) 177-186; DOI: 10.1124/jpet.105.096347.
- Q. Sun, R. Zhu, F. W. Foss, Jr. and T. L. Macdonald, Mechanisms of trovafloxacin hepatotoxicity: studies of a model cyclopropylamine-containing system, Bioorg. Med. Chem. Lett. 17 (2007) 6682-6686; DOI: 10.1016/j.bmd.2007.10.070.
- Q. Sun, R. Zhu, F. W. Foss, Jr. and T. L. Macdonald, In vitro metabolism of a model cyclopropylamine to reactive intermediate: Insights into trovafloxacin-induced hepatotoxicity, Chem. Res. Toxicol. 21 (2008) 711-719; DOI: 10.1021/tx7003085.
- J. M. Domagala, Structure-activity and structure-side-effect relationships for the quinolone antibacterials, J. Antimicrob. Chemother. 33 (1994) 685-706; DOI: 10.1093/jac/33.4.685.
- G. S. Tillotson, Quinolones: structure-activity relationships and future predictions, J. Med. Microb. 44 (1996) 320-324; DOI: 10.1099/00222615-44-5-320.
- L. Mandell and G. Tillotson, Fluoroquinolone safety: An overview evaluating safety and antimicrobial activity profiles based on molecular structure categorized adverse effects, Can. J. Infec. Dis. 13 (2002) 54-61.
- Y. Tsuzuki, K. Tomita, K. Shibamori, Y. Sato, S. Kashimoto and K. Chiba, Synthesis and structure-activity relationships of novel 7-substituted 1,4 dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as anti-tumor agents, part-2, J. Med. Chem. 47 (2004) 2097-2109; DOI: 10.1021/jm0304966.
- M. Paul, A. Gafter-Gvili, A. Fraser and L. Leibovici, The anti-cancer effects of quinolone antibiotics?, Eur. J. Clin. Microbiol. Infect. Dis. 26 (2007) 825-831; DOI: 10.1007/s10096-007-0375-4.
- T. Norris and G. Ferry, Process for Preparing Quinolone and Naphthyridine Carboxylic Acids, U.S. Pat. 6,114,531, 5 Sep. 2005.
- E. Rubinstein, History of quinolones and their side-effects, Chemotherapy 47 (2001) 3-8; 44-48; DOI: 10.1159/000057838.
- P. J. Shaw, A. M. Fullerton, M. A. Scott, P. E. Ganey and R. A. Roth, The role of the hemostatic system in murine liver injury induced by coexposure to lipopolysaccharide and trovafloxacin, a drug with idiosyncratic liability, Toxicol. Appl. Pharmacol. 236 (2009) 293-300; DOI: 10.1016/j.taap.2009.01.018.
- C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Del. Rev. 23 (1997) 4-25; DOI: 10.1016/S0169-409X(00)00129-0.
- D. F. Veber, S. R. Johnson, H. Y. Cheng, B. R. Smith, K. W. Ward and K. D. Kopple, Molecular properties that influence the oral bioavailability of drug candidates, J. Med. Chem. 45 (2002) 2615-2623; DOI: 10.1021/jm020017n.
- P. Ertl, B. Rohde and P. Selzer, Fast calculation of molecular polar surface area as a sum of fragent-based contributions and its application to the prediction of drug transport properties, J. Med. Chem. 43 (2000) 3714-3717; DOI: 10.1021/jm000942e.
- H. O. Kalinowski, S. Berger and S. Braun, 13C-NMR Spektroskopie, Georg Thieme Verlag, Stuttgart 1984.
- R. M. Silverstein, C. C. Bassler and T. C. Morrill, Spectroscopic Identification of Organic Compounds, 5th ed., Wiley, New York 1991.
- G. Fardella, P. Barbetti, I. Chiappini and G. Grandolini, Quantitative analysis of fluoroquinolones by 1H and 19F-NMR spectroscopy, Int. J. Pharm. 121 (1995) 123-127; DOI: 10:1016/0378-5173(95)00038-K.
- A. Zieba, A. Mašlankiewicz and J. Sitkovski, 1H, 13C and 15N NMR spectra of ciprofloxacin, Magn. Reson. Chem. 42 (2004) 903-904; DOI: 10.1002/mrc.1468.